(OTCBB:RGBP) Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell For Solid Tumors
Contributor Since 2014
Business Development-Marketing Consultation-IR
Over 30 years Of Management-Sales-Corporate Finance & IR
Connection for Sources of Pubco & Private Company
Funding Financing & Debt Restructure
www.regenbiopharmainc.com (OTCPK:RGBP)
Regen BioPharma, Inc. Files Patent Application Covering Innate Immune Activating NR2F6 Silenced CAR-T Cell for Solid Tumors
Company Augments Potency of its Existing NR2F6 Silenced CAR-T Approach By Leveraging Innate Immune Activation Molecules
The filing of an application for a United States patent covering synergies between NR2F6 gene-silenced CAR T cells combined with proprietary activators of the innate immune system. While previous work demonstrated that methodologies developed by Regen (protected under Regen's issued US patent #9,091,696) are useful in stimulation of T cell activity, the current application further modifies T cells to express molecules that act as a localized "danger signal" to the immune system.
Remarkable clinical results have been obtained by numerous investigators utilizing CAR T cells in the treatment of leukemia and lymphomas
http://finance.yahoo.com/news/regen-biopharma-inc-files-patent-133000462.html
Recent News Items of Interest:
Regen BioPharma Submits Application to FDA for Orphan Drug Designation for its HemaXellerate Product
http://finance.yahoo.com/news/regen-biopharma-submits-application-fda-133000880.html
Regen BioPharma, Inc. and the National Institutes of Health to Collaborate
http://finance.yahoo.com/news/regen-biopharma-inc-national-institutes-133000075.html
Regen BioPharma, Inc. Receives FDA Clearance to Initiate Clinical Trial of HemaXelleratehttp://finance.yahoo.com/news/regen-biopharma-inc-receives-fda-133000659.html
We believe Regen is a Long Play with imminent Short Term Gain potential.
They are a "Cutting Edge" Bio Tech - Stem Cell R&D Company that offers exponential growth.
Regen in our opinion will one day be either the Leader in many areas of Stem Cell treatment and/or could be a very attractive Candidate for a Buy Out or Merger.
Areas of Focus are:
Various Cancers and the treatment of - Breast, Liver, Kidney, Prostate
(dCellVax is on the verge of & awaits FDA clearance for Phase I Human/Patient clinical trials for Breast Cancer)
Treatment of Rare Blood Disorders & Diseases (HemaXellerate FDA "Cleared/Approved " for Human/Patient clinical trials (aPlastic Anemia) Phase I to commence soon.
Treatment of Leukemia
We can Assist any Publicly Traded Company Gain Greater Exposure Creating Increased Awareness and Liquidity in the Market Place (Retail or Private)
** Contact us for Custom Tailored Plans for Your situation
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.